 Tiziana Life Sciences Ltd NASDAQ:TLSA has reported further positive results from a patient with non-active secondary progressive multiple sclerosis SPMS being treated with the companys intranasal foralumab formerly NI-0401. After receiving intranasal foralumab treatment for six months, the second patient EA2 with SPMS has shown additional clinical improvements as measured by the Expanded Disability Status Scale EDSS, a standard clinical assessment, the company said. 